NYSE:BMY - Bristol-Myers Squibb Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $75.57
  • Forecasted Upside: 1.49 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.4 (-0.53%)

This chart shows the closing price for BMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bristol-Myers Squibb Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMY

Analyst Price Target is $75.57
▲ +1.49% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $75.57, with a high forecast of $92.00 and a low forecast of $49.00. The average price target represents a 1.49% upside from the last price of $74.46.

This chart shows the closing price for BMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Bristol-Myers Squibb. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/28/2022Atlantic SecuritiesBoost Price TargetOverweight$82.00 ➝ $83.00Low
7/28/2022JPMorgan Chase & Co.Boost Price Target$80.00 ➝ $85.00Low
7/27/2022UBS GroupBoost Price TargetOutperform$73.00Low
6/6/2022Bank of AmericaBoost Price TargetBuy ➝ Buy$78.00 ➝ $80.00Low
6/3/2022CitigroupReiterated RatingBuy$90.00Low
6/3/2022Raymond JamesDowngradeOutperform ➝ Market PerformLow
5/26/2022CitigroupBoost Price TargetBuy$75.00 ➝ $90.00Low
5/17/2022Wells Fargo & CompanyBoost Price TargetEqual Weight$65.00 ➝ $70.00Medium
5/2/2022Truist FinancialBoost Price Target$76.00 ➝ $81.00Low
5/2/2022BMO Capital MarketsBoost Price Target$87.00 ➝ $92.00Low
5/2/2022GuggenheimBoost Price Target$72.00 ➝ $80.00Low
5/2/2022BarclaysBoost Price Target$66.00 ➝ $68.00Low
4/6/2022Morgan StanleyLower Price TargetEqual Weight ➝ Underweight$66.00 ➝ $64.00Low
3/30/2022BMO Capital MarketsBoost Price TargetOutperform$74.00 ➝ $81.00Low
3/2/2022Wells Fargo & CompanyBoost Price TargetEqual Weight$60.00 ➝ $65.00Low
12/17/2021The Goldman Sachs GroupInitiated CoverageBuy$72.00Medium
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$58.00Low
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$72.00High
11/1/2021ArgusDowngradeBuy ➝ Hold$49.00Low
10/28/2021BarclaysLower Price TargetEqual Weight$68.00 ➝ $66.00Low
10/12/2021Morgan StanleyLower Price TargetEqual Weight$71.00 ➝ $66.00Low
10/11/2021Berenberg BankLower Price TargetBuy$75.00 ➝ $71.00Low
10/8/2021BarclaysLower Price TargetEqual Weight$71.00 ➝ $68.00High
7/29/2021Morgan StanleyBoost Price TargetEqual Weight$62.00 ➝ $71.00Low
7/28/2021Truist FinancialInitiated CoverageBuy$74.00Low
7/28/2021Bank of AmericaReiterated RatingBuyHigh
5/6/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$62.00Low
4/30/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$70.00 ➝ $62.00Low
4/13/2021Truist FinancialUpgradeHold ➝ BuyLow
12/15/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
11/30/2020Smith Barney CitigroupBoost Price Target$73.00 ➝ $77.00Low
11/16/2020Societe GeneraleUpgradeHold ➝ Buy$76.00Low
11/10/2020Sanford C. BernsteinReiterated RatingMarket Perform$72.00Low
11/6/2020GabelliDowngradeBuy ➝ HoldLow
10/23/2020Truist FinancialInitiated CoverageHold$65.00Medium
10/19/2020GuggenheimUpgradeNeutral ➝ Buy$70.00Medium
10/16/2020JPMorgan Chase & Co.Boost Price TargetOverweight$74.00 ➝ $78.00Low
9/29/2020Berenberg BankInitiated CoverageBuy$73.00Low
9/25/2020Raymond JamesReiterated RatingBuyLow
9/22/2020Raymond JamesBoost Price TargetOutperform$75.00 ➝ $78.00Medium
8/12/2020Morgan StanleyBoost Price TargetOverweight$64.00 ➝ $66.00Low
7/28/2020Raymond JamesInitiated CoverageOutperform$75.00Medium
7/26/2020CfraReiterated RatingBuy$70.00Low
6/2/2020Cantor FitzgeraldBoost Price Target$68.00 ➝ $88.00Low
6/1/2020William BlairReiterated RatingBuyLow
5/15/2020Bank of AmericaReiterated RatingBuy$80.00Low
5/15/2020William BlairReiterated RatingBuyHigh
5/7/2020CfraBoost Price TargetBuy$69.00 ➝ $70.00Low
4/2/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$64.00Low
4/1/2020Bank of AmericaReiterated RatingBuy$75.00Low
3/23/2020Societe GeneraleDowngradeBuy ➝ Hold$50.00High
2/27/2020BarclaysInitiated CoverageEqual Weight$69.00High
2/14/2020William BlairReiterated RatingBuyLow
1/6/2020CitigroupUpgradeNeutral ➝ Buy$73.00Low
12/13/2019William BlairReiterated RatingBuyLow
12/13/2019ArgusUpgradeHold ➝ Buy$80.00Medium
11/27/2019GabelliInitiated CoverageBuyMedium
11/25/2019MizuhoInitiated CoverageBuyMedium
11/22/2019Morgan StanleyInitiated CoverageEqual Weight$60.00Low
11/18/2019William BlairReiterated RatingOutperformHigh
11/1/2019Wells Fargo & CompanySet Price TargetHold$110.00Low
11/1/2019SVB LeerinkSet Price TargetHold$115.00N/A
11/1/2019Wolfe ResearchSet Price TargetBuy$66.00N/A
11/1/2019Standpoint ResearchDowngradeBuy ➝ HoldLow
11/1/2019Robert W. BairdDowngradeOutperform ➝ Neutral$101.00Low
10/23/2019UBS GroupBoost Price TargetNeutral$51.00 ➝ $53.00Medium
10/20/2019MizuhoReiterated RatingHold$100.00Low
10/16/2019Bank of AmericaInitiated CoverageBuy$60.00Medium
10/10/2019Bank of AmericaBoost Price TargetNeutral$49.00 ➝ $50.00Low
9/13/2019JPMorgan Chase & Co.Set Price TargetBuy$62.00Low
9/3/2019Bank of AmericaBoost Price TargetNeutral$46.00 ➝ $49.00Low
8/19/2019MizuhoDowngradeBuy ➝ Neutral$103.00 ➝ $100.00Low
8/14/2019Atlantic SecuritiesUpgradeNeutral ➝ Overweight$63.00High
7/30/2019CowenReiterated RatingHold$102.00Low
7/3/2019MizuhoReiterated RatingBuy$103.00Low
6/25/2019MizuhoReiterated RatingBuy$103.00Low
6/13/2019UBS GroupLower Price TargetNeutral$55.00 ➝ $51.00Low
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$54.00High
5/20/2019ArgusDowngradeBuy ➝ Hold$46.36Low
5/16/2019MizuhoReiterated RatingBuy$103.00Low
5/3/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$62.00High
5/3/2019BarclaysDowngradeOverweight ➝ Equal Weight$102.00Medium
5/3/2019BarclaysUpgradeEqual Weight ➝ Overweight$53.00 ➝ $55.00High
4/17/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$62.00 ➝ $63.00Low
4/5/2019MizuhoSet Price TargetBuy$103.00Low
4/5/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$94.00Low
4/1/2019Sanford C. BernsteinDowngradeOutperform ➝ Market PerformLow
4/1/2019Atlantic SecuritiesDowngradeOverweight ➝ Neutral$94.34Low
4/1/2019UBS GroupDowngradeBuy ➝ Neutral$94.00 ➝ $102.00Low
4/1/2019William BlairDowngradeOutperform ➝ Market PerformLow
3/20/2019BMO Capital MarketsBoost Price TargetOutperform$62.00Medium
2/28/2019William BlairReiterated RatingBuyHigh
2/26/2019CowenInitiated CoverageMarket Perform$102.00Low
2/19/2019Bank of AmericaLower Price TargetNeutral ➝ Neutral$53.00 ➝ $51.00Low
2/19/2019BMO Capital MarketsReiterated RatingBuy$59.00Low
2/15/2019Credit Suisse GroupReiterated RatingHold$59.00Low
2/4/2019Credit Suisse GroupSet Price TargetHold$59.00High
2/1/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$95.00Low
1/31/2019Cantor FitzgeraldReiterated RatingBuy$100.00Medium
1/25/2019Bank of AmericaSet Price TargetHold$53.00Low
1/15/2019Societe GeneraleUpgradeSell ➝ BuyLow
1/4/2019Edward JonesDowngradeBuy ➝ HoldMedium
1/4/2019Robert W. BairdUpgradeNeutral ➝ Outperform$92.00High
1/3/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$71.00 ➝ $88.00High
1/3/2019Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$90.00 ➝ $84.00High
1/3/2019SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
1/3/2019BMO Capital MarketsReiterated RatingBuy$60.00High
1/3/2019Cantor FitzgeraldReiterated RatingBuy$100.00High
12/20/2018Morgan StanleySet Price TargetHold$54.00Medium
12/20/2018BTIG ResearchInitiated CoverageNeutral ➝ NeutralHigh
12/19/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$93.00 ➝ $88.00Medium
12/17/2018CitigroupLower Price TargetNeutral ➝ Neutral$100.00 ➝ $77.00Low
12/13/2018Credit Suisse GroupReiterated RatingHold$59.00High
12/6/2018BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$60.00 ➝ $60.00High
11/27/2018BMO Capital MarketsLower Price TargetMarket Perform$56.00Medium
11/27/2018William BlairReiterated RatingOutperformMedium
11/16/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$55.00 ➝ $58.00Low
11/14/2018Societe GeneraleSet Price TargetSell$47.00Low
11/6/2018Morgan StanleyLower Price TargetEqual Weight ➝ Hold$63.00 ➝ $59.00Low
10/30/2018MizuhoSet Price TargetBuy$117.00Medium
10/27/2018UBS GroupSet Price TargetBuy$94.00Medium
10/26/2018SVB LeerinkSet Price TargetHold$112.00Low
10/25/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
10/23/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$57.00 ➝ $54.00Medium
10/23/2018Wolfe ResearchInitiated CoverageOutperform$66.00Low
10/22/2018William BlairReiterated RatingOutperformHigh
10/22/2018CitigroupDowngradeBuy ➝ Neutral$62.00 ➝ $57.00High
10/14/2018Credit Suisse GroupSet Price TargetHold$61.00Low
10/12/2018BarclaysBoost Price TargetEqual Weight$55.00 ➝ $58.00Low
10/11/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
10/8/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$70.00 ➝ $74.00Medium
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$100.00Low
9/12/2018Credit Suisse GroupReiterated RatingHold$61.00Low
8/8/2018Atlantic SecuritiesUpgradeUnderweight ➝ Neutral$57.00Medium
7/31/2018MizuhoReiterated RatingBuy$129.00Low
7/31/2018SunTrust BanksReiterated RatingBuy$67.00Low
7/27/2018SunTrust BanksReiterated RatingHold$101.00Low
7/27/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$91.00 ➝ $93.00N/A
7/27/2018Credit Suisse GroupBoost Price TargetNeutral ➝ Neutral$58.00 ➝ $61.00N/A
7/23/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$47.00 ➝ $51.00Medium
7/22/2018BMO Capital MarketsReiterated RatingHoldMedium
7/15/2018Jefferies Financial GroupSet Price TargetHold$58.00Low
7/13/2018Morgan StanleyBoost Price TargetEqual Weight$90.00 ➝ $91.00Low
7/10/2018CowenReiterated RatingBuy$150.00Low
7/10/2018MizuhoReiterated RatingBuy$118.00Low
6/21/2018BMO Capital MarketsReiterated RatingHold$47.00High
6/18/2018Standpoint ResearchUpgradeHold ➝ BuyLow
6/1/2018Cantor FitzgeraldSet Price TargetHold$112.00Low
5/29/2018SunTrust BanksLower Price TargetHold$106.00 ➝ $96.00Low
5/24/2018Cantor FitzgeraldSet Price TargetHold$112.00Low
5/23/2018ArgusDowngradeBuy ➝ HoldLow
5/23/2018Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$102.00Low
5/21/2018UBS GroupDowngradeBuy ➝ Neutral$57.00Low
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$93.00 ➝ $90.00Low
5/7/2018SVB LeerinkReiterated RatingBuy$123.00 ➝ $115.00Medium
5/7/2018Royal Bank of CanadaDowngradeTop Pick ➝ Outperform$120.00High
5/6/2018BarclaysSet Price TargetBuy$107.00Medium
5/5/2018Cantor FitzgeraldSet Price TargetHold$112.00Medium
5/5/2018Credit Suisse GroupSet Price TargetBuy$129.00Medium
4/30/2018Evercore ISIReiterated RatingBuyLow
4/27/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$65.00 ➝ $55.00Low
4/27/2018BMO Capital MarketsUpgradeUnderperform ➝ Market PerformLow
4/26/2018Credit Suisse GroupSet Price TargetHold$58.00Low
4/26/2018BMO Capital MarketsReiterated RatingUnderperform ➝ Sell$47.00Low
4/20/2018CowenReiterated RatingHold$60.00Low
4/18/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$51.00 ➝ $47.00Low
4/17/2018Credit Suisse GroupSet Price TargetBuy$129.00Low
4/17/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$68.00 ➝ $61.00Low
4/17/2018William BlairReiterated RatingOutperformHigh
4/17/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$54.08 ➝ $58.00High
4/13/2018Morgan StanleyReiterated RatingEqual ➝ Equal Weight$93.00Low
4/13/2018Jefferies Financial GroupReiterated RatingHold$66.00Low
4/2/2018Cantor FitzgeraldSet Price TargetHold$112.00Low
3/28/2018SVB LeerinkSet Price TargetBuy$123.00High
3/26/2018The Goldman Sachs GroupLower Price TargetSell ➝ Sell$97.00 ➝ $85.00Low
3/23/2018Jefferies Financial GroupSet Price TargetHold$70.00Medium
3/21/2018ArgusLower Price TargetBuy$75.00 ➝ $66.43Low
3/21/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$110.00Low
3/20/2018JPMorgan Chase & Co.Set Price TargetOverweight ➝ Overweight$70.00 ➝ $75.00Low
3/5/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$64.00 ➝ $68.00Medium
3/1/2018Robert W. BairdReiterated RatingHold$92.00Medium
3/1/2018Credit Suisse GroupSet Price TargetBuy$129.00Low
2/28/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$144.00 ➝ $139.00High
2/28/2018William BlairReiterated RatingBuyHigh
2/28/2018DZ BankDowngradeBuy ➝ HoldHigh
2/28/2018Credit Suisse GroupDowngradeBuy ➝ Hold$129.00 ➝ $90.00High
2/28/2018UBS GroupSet Price TargetBuy$106.00High
2/28/2018Stifel NicolausReiterated RatingBuy ➝ Buy$130.00 ➝ $128.00High
2/28/2018SunTrust BanksDowngradeBuy ➝ Hold$139.00 ➝ $106.00High
2/27/2018Cantor FitzgeraldSet Price TargetHold$112.00High
2/26/2018Jefferies Financial GroupSet Price TargetHold$72.00Low
2/16/2018CitigroupSet Price TargetBuy$78.00Low
2/15/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$51.56 ➝ $78.00High
2/14/2018BMO Capital MarketsSet Price TargetSell$51.00Low
2/13/2018BarclaysUpgradeEqual Weight ➝ Overweight$91.51 ➝ $105.00Low
2/6/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$52.00 ➝ $51.00High
2/6/2018SVB LeerinkBoost Price TargetOutperform ➝ Positive$71.00 ➝ $76.00Medium
2/4/2018MizuhoReiterated RatingBuy$128.00High
1/29/2018Cantor FitzgeraldReiterated RatingHold$112.00Medium
1/26/2018SunTrust BanksReiterated RatingBuy$127.00 ➝ $139.00Low
1/24/2018BMO Capital MarketsReiterated RatingBuy$144.00Low
1/23/2018Royal Bank of CanadaReiterated RatingTop PickLow
1/23/2018BTIG ResearchReiterated RatingHoldMedium
1/23/2018Cantor FitzgeraldSet Price TargetHold$112.00Medium
1/22/2018Credit Suisse GroupSet Price TargetHold$62.00Low
1/22/2018BMO Capital MarketsReiterated RatingSell$52.00Low
1/18/2018Piper Jaffray CompaniesReiterated RatingHold$104.00Low
1/17/2018Cantor FitzgeraldSet Price TargetHold$112.00Medium
1/17/2018MizuhoSet Price TargetBuy$128.00High
1/10/2018GuggenheimReiterated RatingBuy$147.00Low
1/8/2018SunTrust BanksSet Price TargetBuy$127.00Medium
1/8/2018Credit Suisse GroupSet Price TargetBuy$125.00Medium
1/8/2018Stifel NicolausSet Price TargetBuy$130.00Medium
1/8/2018Deutsche Bank AktiengesellschaftSet Price TargetHold$110.00Low
1/8/2018OppenheimerSet Price TargetBuy$166.00High
1/8/2018Cantor FitzgeraldSet Price TargetHold$112.00High
1/5/2018MizuhoSet Price TargetBuy$128.00Low
1/5/2018Bank of AmericaDowngradeBuy ➝ Neutral$104.68 ➝ $120.00Medium
1/4/2018Royal Bank of CanadaReiterated RatingBuy$147.00High
12/31/2017SunTrust BanksSet Price TargetBuy$127.00Medium
12/30/2017Stifel NicolausLower Price TargetBuy$149.00 ➝ $130.00N/A
12/29/2017Cantor FitzgeraldSet Price TargetHold$112.00Low
12/28/2017OppenheimerSet Price TargetBuy$166.00Low
12/28/2017Credit Suisse GroupSet Price TargetBuy$123.00Low
12/27/2017Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$121.00High
12/26/2017MizuhoSet Price TargetBuy$128.00Low
12/25/2017GuggenheimSet Price TargetBuy$152.00Low
12/25/2017SunTrust BanksSet Price TargetBuy$127.00Low
12/22/2017SVB LeerinkReiterated RatingBuy$120.00Low
12/22/2017BMO Capital MarketsReiterated RatingBuy$147.00Low
12/22/2017CitigroupReiterated RatingHoldMedium
12/22/2017OppenheimerSet Price TargetBuy$166.00Low
12/22/2017Credit Suisse GroupSet Price TargetBuy ➝ Buy$128.00 ➝ $123.00High
12/22/2017Stifel NicolausLower Price TargetBuy ➝ Buy$149.00 ➝ $130.00High
12/21/2017Cantor FitzgeraldSet Price TargetHold$112.00High
12/14/2017OppenheimerSet Price TargetBuy$166.00Low
12/13/2017SVB LeerinkReiterated RatingBuy$120.00Low
12/12/2017Credit Suisse GroupSet Price TargetBuy$128.00Low
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$114.00Low
12/11/2017BMO Capital MarketsSet Price TargetSell$49.00Low
12/11/2017Cantor FitzgeraldSet Price TargetHold$112.00High
12/10/2017Piper Jaffray CompaniesReiterated RatingHoldHigh
12/8/2017Atlantic SecuritiesUpgradeNeutral ➝ OverweightHigh
12/5/2017CitigroupSet Price TargetBuy$72.00Low
11/17/2017BMO Capital MarketsBoost Price TargetOutperform$148.00 ➝ $155.00N/A
11/16/2017OppenheimerSet Price TargetBuy$166.00N/A
11/3/2017MizuhoReiterated RatingBuyN/A
10/30/2017OppenheimerReiterated RatingBuy$163.00 ➝ $166.00N/A
10/30/2017SunTrust BanksUpgradeHold ➝ BuyN/A
10/30/2017Cantor FitzgeraldReiterated RatingHold$112.00N/A
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$123.00N/A
10/27/2017UBS GroupLower Price TargetBuy$146.00 ➝ $120.00N/A
10/27/2017BMO Capital MarketsLower Price TargetOutperform$163.00 ➝ $148.00N/A
10/27/2017Credit Suisse GroupReiterated RatingHold$58.00 ➝ $61.00N/A
10/27/2017BarclaysReiterated RatingEqual Weight ➝ Equal Weight$135.00 ➝ $105.00N/A
10/27/2017CitigroupLower Price TargetNeutral$140.00 ➝ $102.00N/A
10/27/2017SunTrust BanksLower Price TargetBuy ➝ Buy$156.00 ➝ $127.00N/A
10/27/2017Royal Bank of CanadaLower Price TargetTop Pick$166.00 ➝ $148.00N/A
10/27/2017Cantor FitzgeraldDowngradeOverweight ➝ NeutralN/A
10/27/2017The Goldman Sachs GroupReiterated RatingSell$116.00 ➝ $91.00N/A
10/27/2017Morgan StanleyUpgradeUnderweight ➝ Equal WeightN/A
10/27/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$60.00N/A
10/27/2017Robert W. BairdReiterated RatingHold$103.00N/A
10/26/2017UBS GroupDowngradeStrong-Buy ➝ Market Perform$160.00N/A
10/26/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
10/26/2017BMO Capital MarketsSet Price TargetSell$49.00N/A
10/26/2017Cantor FitzgeraldSet Price TargetBuy$162.00N/A
10/25/2017CitigroupSet Price TargetBuy$72.00N/A
10/23/2017GuggenheimInitiated CoverageBuy ➝ Buy$160.00N/A
10/23/2017SVB LeerinkBoost Price TargetOutperform$61.00 ➝ $72.00N/A
10/23/2017Morgan StanleyLower Price TargetUnderweight ➝ Underweight$120.00 ➝ $115.00N/A
10/23/2017Piper Jaffray CompaniesReiterated RatingNeutral ➝ Neutral$133.00N/A
10/22/2017BTIG ResearchReiterated RatingHoldN/A
10/20/2017SVB LeerinkReiterated RatingBuy$156.00N/A
10/20/2017OppenheimerReiterated RatingBuy$170.00N/A
10/20/2017Wells Fargo & CompanyReiterated RatingBuy$163.00N/A
10/20/2017BarclaysLower Price TargetEqual Weight$135.00 ➝ $105.00N/A
10/20/2017William BlairReiterated RatingOutperformN/A
10/20/2017UBS GroupLower Price TargetBuy ➝ Buy$153.00 ➝ $146.00N/A
10/20/2017Stifel NicolausLower Price TargetBuy$155.00 ➝ $149.00N/A
10/20/2017CitigroupDowngradeBuy ➝ NeutralN/A
10/20/2017Robert W. BairdDowngradeOutperform ➝ Neutral$162.00 ➝ $136.00N/A
10/18/2017CitigroupBoost Price TargetBuy$72.00N/A
10/17/2017Sanford C. BernsteinInitiated CoverageOutperform$162.00N/A
10/17/2017BMO Capital MarketsBoost Price TargetPositive$160.00 ➝ $167.00N/A
10/16/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/16/2017Jefferies Financial GroupReiterated RatingBuy$160.00N/A
10/16/2017Cantor FitzgeraldSet Price TargetBuy$162.00N/A
10/16/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$72.00N/A
10/13/2017BarclaysBoost Price TargetEqual Weight$135.00 ➝ $140.00N/A
10/12/2017BMO Capital MarketsSet Price TargetSell$49.00N/A
10/6/2017UBS GroupReiterated RatingBuy$62.00 ➝ $72.00N/A
10/5/2017Royal Bank of CanadaReiterated RatingBuy$173.00N/A
10/5/2017Morgan StanleyDowngradeEqual Weight ➝ Underweight$120.00N/A
9/27/2017Jefferies Financial GroupReiterated RatingBuy$72.00Low
9/26/2017Cantor FitzgeraldReiterated RatingBuy$162.00Low
9/21/2017Robert W. BairdReiterated RatingBuy$162.00Low
9/19/2017CowenReiterated RatingHold$65.00Low
9/15/2017Jefferies Financial GroupReiterated RatingBuy$160.00Low
9/15/2017MizuhoBoost Price TargetBuy ➝ Buy$134.00 ➝ $158.00Medium
9/14/2017Royal Bank of CanadaInitiated CoverageTop Pick ➝ Top Pick$176.00High
9/13/2017Bank of AmericaReiterated RatingBuyLow
9/12/2017CowenReiterated RatingBuy$150.00Low
9/12/2017Hilliard LyonsDowngradeLong-term Buy ➝ Neutral$65.00Low
9/11/2017Jefferies Financial GroupBoost Price TargetBuy$66.00 ➝ $72.00Low
9/8/2017Credit Suisse GroupReiterated RatingNeutral ➝ HoldLow
9/7/2017The Goldman Sachs GroupReiterated RatingBuy$62.00 ➝ $65.00Low
9/5/2017BTIG ResearchReiterated RatingNeutralLow
9/4/2017BMO Capital MarketsReiterated RatingSell$49.00Low
8/28/2017Cantor FitzgeraldReiterated RatingBuyLow
8/24/2017Jefferies Financial GroupReiterated RatingBuy$63.00 ➝ $66.00Low
8/22/2017Cantor FitzgeraldReiterated RatingBuyLow
8/16/2017Credit Suisse GroupSet Price TargetHold$58.00Medium
8/14/2017CowenSet Price TargetHold$65.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 20 very positive mentions
  • 30 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
  • 18 very positive mentions
  • 37 positive mentions
  • 7 negative mentions
  • 8 very negative mentions
  • 25 very positive mentions
  • 34 positive mentions
  • 5 negative mentions
  • 8 very negative mentions
  • 10 very positive mentions
  • 51 positive mentions
  • 5 negative mentions
  • 6 very negative mentions
  • 18 very positive mentions
  • 51 positive mentions
  • 9 negative mentions
  • 7 very negative mentions
  • 17 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 6 very negative mentions
  • 18 very positive mentions
  • 57 positive mentions
  • 7 negative mentions
  • 7 very negative mentions

Current Sentiment

  • 18 very positive mentions
  • 57 positive mentions
  • 7 negative mentions
  • 7 very negative mentions

Recent Stories by Sentiment

Bristol-Myers Squibb logo
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Read More

Today's Range

Now: $74.46
Low: $74.28
High: $75.52

50 Day Range

MA: $74.94
Low: $72.12
High: $79.98

52 Week Range

Now: $74.46
Low: $53.22
High: $80.59


5,824,475 shs

Average Volume

9,090,937 shs

Market Capitalization

$158.99 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Bristol-Myers Squibb?

The following Wall Street analysts have issued stock ratings on Bristol-Myers Squibb in the last twelve months: Argus, Atlantic Securities, Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Raymond James, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for BMY.

What is the current price target for Bristol-Myers Squibb?

14 Wall Street analysts have set twelve-month price targets for Bristol-Myers Squibb in the last year. Their average twelve-month price target is $75.57, suggesting a possible upside of 1.5%. BMO Capital Markets has the highest price target set, predicting BMY will reach $92.00 in the next twelve months. Argus has the lowest price target set, forecasting a price of $49.00 for Bristol-Myers Squibb in the next year.
View the latest price targets for BMY.

What is the current consensus analyst rating for Bristol-Myers Squibb?

Bristol-Myers Squibb currently has 1 sell rating, 4 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMY will outperform the market and that investors should add to their positions of Bristol-Myers Squibb.
View the latest ratings for BMY.

What other companies compete with Bristol-Myers Squibb?

Other companies that are similar to Bristol-Myers Squibb include Merck & Co., Inc., Zoetis, AbbVie, Pfizer and Eli Lilly and. Learn More about companies similar to Bristol-Myers Squibb.

How do I contact Bristol-Myers Squibb's investor relations team?

Bristol-Myers Squibb's physical mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company's listed phone number is (212) 546-4000 and its investor relations email address is [email protected] The official website for Bristol-Myers Squibb is www.bms.com. Learn More about contacing Bristol-Myers Squibb investor relations.